 |
49 Diseases |  |
63 Trials |
|
63 Trials |  |
669 News |  |
| 1234567891011» |
- | methylprednisolone sodium succinate / Generic mfg., prednisone delayed-release tablet / Generic mfg.
Trial completion date, Trial primary completion date: High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov) - May 1, 2024
P1/2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | abiraterone acetate / Generic mfg.
New P2 trial, MRI: Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone (clinicaltrials.gov) - Apr 25, 2024
P2, N=32, Not yet recruiting, Sponsor: Ivan de Kouchkovsky, MD
- | Onureg (azacitidine oral) / BMS
Trial completion date, Trial primary completion date: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 17, 2024
P2/3, N=422, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
- | Ukoniq (umbralisib) / TG Therap, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov) - Apr 17, 2024
P2, N=95, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026 Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
- | prednisone delayed-release tablet / Generic mfg.
Journal: Is the use of gonad protection protectors necessary during infants chest radiography? (Pubmed Central) - Apr 13, 2024
No significant difference was observed in gonad dose measurements with and without the gonad protector during infants chest radiography. We believe that gonadal protector wearing is not necessary.
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 5, 2024
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | methylprednisolone sodium succinate / Generic mfg., prednisone delayed-release tablet / Generic mfg.
Enrollment open, Enrollment change: High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
We believe that gonadal protector wearing is not necessary. Active, not recruiting --> Recruiting | N=15 --> 35
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Trial completion date, Combination therapy, Metastases: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=83, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Remicade (infliximab) / J&J
Trial completion date, Trial termination, Trial primary completion date, IO biomarker: ECOG-ACRIN-EAQ172: Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (clinicaltrials.gov) - Mar 25, 2024
P2, N=1, Terminated, Sponsor: ECOG-ACRIN Cancer Research Group
Active, not recruiting --> Recruiting | N=15 --> 35 Trial completion date: Jul 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Dec 2023; Slow accrual
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 21, 2024
P1, N=24, Recruiting, Sponsor: Yazeed Sawalha
Trial completion date: Jul 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Dec 2023; Slow accrual Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 | Suspended --> Recruiting
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment open, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Mar 19, 2024
P2, N=78, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 | Suspended --> Recruiting Active, not recruiting --> Recruiting
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial termination: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 19, 2024
P1, N=15, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Recruiting Trial completion date: Nov 2028 --> Mar 2024 | Active, not recruiting --> Terminated; Decision made to not move forward with Phase II portion of trial
- | Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion date, Trial primary completion date, Checkpoint inhibition: Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis (clinicaltrials.gov) - Mar 15, 2024
P2, N=42, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Nov 2028 --> Mar 2024 | Active, not recruiting --> Terminated; Decision made to not move forward with Phase II portion of trial Trial completion date: Jun 2023 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jun 2030
- | melphalan / Generic mfg., lenalidomide / Generic mfg., thalidomide / Generic mfg.
Trial completion date: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Mar 12, 2024
P3, N=306, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Rituxan (rituximab) / Roche
GLOMERULOPATIA COLAPSANTE (SAT-297; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1725;
Trial completion date: Jun 2023 --> Jun 2030 | Trial primary completion date: Jun 2023 --> Jun 2030 Historia de la enfermedad actual: acude refiriendo que el d
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 2, 2024
P2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Historia de la enfermedad actual: acude refiriendo que el d Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Metastases: Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 25, 2024
P2, N=7, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2024 --> Jan 2028
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Feb 19, 2024
P2, N=48, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2024 --> Jan 2028 Trial completion date: Dec 2023 --> Dec 2024
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment closed, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Feb 15, 2024
P2, N=78, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date, Metastases: c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=37, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> Jul 2024
- | Rituxan (rituximab) / Roche
Trial completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Jul 2024 Trial completion date: Dec 2023 --> Dec 2024
- | dasatinib / Generic mfg.
Trial completion date: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 15, 2024
P2, N=97, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Jan 2024 --> Jan 2025
- | Sarclisa (isatuximab-irfc) / Sanofi
Phase classification, Trial completion date: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2024
P1, N=15, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jan 2024 --> Jan 2025 Phase classification: P1/2 --> P1 | Trial completion date: Dec 2023 --> Nov 2028
- || Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
New P1/2 trial, Combination therapy: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 7, 2024
P1/2, N=40, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Enrollment closed: Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov) - Jan 28, 2024
P1, N=50, Active, not recruiting, Sponsor: University of Chicago
Phase classification: P1/2 --> P1 | Trial completion date: Dec 2023 --> Nov 2028 Recruiting --> Active, not recruiting
- Libtayo (cemiplimab-rwlc) / Regeneron
Phase classification, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jan 25, 2024
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Phase classification: P1 --> P1/2
- ||||||| itacitinib (INCB039110) / Incyte
Trial termination: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Jan 23, 2024
P2/3, N=155, Terminated, Sponsor: Incyte Corporation
Phase classification: P1 --> P1/2 Active, not recruiting --> Terminated; The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jan 3, 2024
P1, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Terminated; The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision. Trial completion date: Jan 2024 --> Jan 2025
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
Trial completion date, Trial primary completion date: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Jan 3, 2024
P2, N=70, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jan 2024 --> Jan 2025 Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
- | Rinvoq (upadacitinib) / AbbVie
Trial completion date, Trial primary completion date: A Trial for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - Dec 30, 2023
P4, N=162, Recruiting, Sponsor: Berinstein, Jeffrey
- | Remicade (infliximab) / J&J
Enrollment closed, Enrollment change, IO biomarker: ECOG-ACRIN-EAQ172: Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (clinicaltrials.gov) - Dec 29, 2023
P2, N=1, Active, not recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027 Recruiting --> Active, not recruiting | N=36 --> 1
- | Venclexta (venetoclax) / Roche, AbbVie
Enrollment closed: A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - Dec 18, 2023
P2/3, N=363, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=36 --> 1 Suspended --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 7, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- | methylprednisolone sodium succinate / Generic mfg., prednisone delayed-release tablet / Generic mfg.
Enrollment closed, Enrollment change: High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov) - Dec 7, 2023
P1/2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Recruiting --> Active, not recruiting | N=25 --> 15
- | revumenib (SNDX-5613) / Syndax Pharma
Enrollment open, Combination therapy: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (clinicaltrials.gov) - Dec 5, 2023
P2, N=78, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=25 --> 15 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Combination therapy, Metastases: Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (clinicaltrials.gov) - Dec 4, 2023
P1/2, N=16, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Aug 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 30, 2023
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Aug 2024 Trial completion date: Mar 2030 --> Jun 2029 | Trial primary completion date: Mar 2030 --> Jun 2029
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Nov 21, 2023
P1/2, N=107, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2030 --> Jun 2029 | Trial primary completion date: Mar 2030 --> Jun 2029 Phase classification: P2 --> P1/2
- | Rinvoq (upadacitinib) / AbbVie
Enrollment open: A Trial for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - Nov 13, 2023
P4, N=162, Recruiting, Sponsor: Berinstein, Jeffrey
Phase classification: P2 --> P1/2 Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 12, 2023
P1/2, N=17, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Nov 2023 | Trial primary completion date: Nov 2024 --> Nov 2023
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Nov 12, 2023
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Nov 2023 | Trial primary completion date: Nov 2024 --> Nov 2023 Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial completion date, Trial primary completion date: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025 Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 2, 2023
P3, N=6720, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026 Suspended --> Recruiting
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion date, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Oct 19, 2023
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial completion date: Mar 2024 --> Sep 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2024 --> Sep 2024 Trial completion date: Oct 2023 --> Sep 2024
- | Calquence (acalabrutinib) / AstraZeneca
Trial primary completion date: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Oct 13, 2023
P2, N=45, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Oct 2023 --> Sep 2024 Trial primary completion date: Sep 2025 --> Aug 2024
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Sep 28, 2023
P3, N=5937, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2025 --> Aug 2024 Trial completion date: Jan 2024 --> Sep 2024
- | lenalidomide / Generic mfg.
Trial completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - Sep 28, 2023
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2024 --> Sep 2024 Trial completion date: Dec 2026 --> Dec 2025
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 22, 2023
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2026 --> Dec 2025 Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Metastases: Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 21, 2023
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026 Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024